Abstract
Increased tubular epithelial cell proliferation with fluid secretion is a key hallmark of autosomal dominant polycystic kidney disease (ADPKD). With disruption of either PKD1 or PKD2, the main causative genes of ADPKD, intracellular calcium homeostasis and cAMP accumulation are disrupted, which in turn leads to altered signaling in the pathways that regulate cell proliferation. These dysregulations finally stimulate the development of fluid-filled cysts originating from abnormally proliferating renal tubular cells. In addition, dysregulated apoptosis is observed in dilated cystic tubules. An imbalance between cell proliferation and apoptosis seems to contribute to cyst growth and renal tissue remodeling in ADPKD. In this section, the mechanisms through which cell proliferation and apoptosis are involved in disease progression, and further, how those signaling pathways impinge on each other in ADPKD will be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281(5381):1305–1308
Bai CX, Giamarchi A, Rodat-Despoix L, Padilla F, Downs T, Tsiokas L, Delmas P (2008) Formation of a new receptor-operated channel by heteromeric assembly of TRPP2 and TRPC1 subunits. EMBO Rep 9(5):472–479. doi:10.1038/embor.2008.29
Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG (2002) PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109(2):157–168
Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444(7121):949–952. doi:10.1038/nature05348
Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (2015) Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol 11(8):451–464. doi:10.1038/nrneph.2015.39
Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29(9):2359–2371. doi:10.1128/MCB.01259-08
Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4(5):476–495
Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, Edelstein CL (2002) Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int 61(4):1220–1230. doi:10.1046/j.1523-1755.2002.00250.x
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516. doi:10.1080/01926230701320337
Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411(6835):342–348. doi:10.1038/35077213
Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9(10):1323–1326. doi:10.1038/nm935
Goilav B (2011) Apoptosis in polycystic kidney disease. Biochim Biophys Acta 1812(10):1272–1280. doi:10.1016/j.bbadis.2011.01.006
Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF (2001) Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2 + -permeable nonselective cation channel. Proc Natl Acad Sci U S A 98(3):1182–1187
Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321–337. doi:10.1146/annurev.med.60.101707.125712
Ibraghimov-Beskrovnaya O (2007) Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6(7):776–779
Joshi M, Kulkarni A, Pal JK (2013) Small molecule modulators of eukaryotic initiation factor 2alpha kinases, the key regulators of protein synthesis. Biochimie 95(11):1980–1990. doi:10.1016/j.biochi.2013.07.030
Lanoix J, D’Agati V, Szabolcs M, Trudel M (1996) Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13(6):1153–1160
Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589–3594. doi:10.1242/jcs.051011
LaRiviere WB, Irazabal MV, Torres VE (2015) Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl Res J Lab Clin Med 165(4):488–498. doi:10.1016/j.trsl.2014.11.003
Li Y, Wright JM, Qian F, Germino GG, Guggino WB (2005) Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J Biol Chem 280(50):41298–41306. doi:10.1074/jbc.M510082200
Liang G, Yang J, Wang Z, Li Q, Tang Y, Chen XZ (2008) Polycystin-2 down-regulates cell proliferation via promoting PERK-dependent phosphorylation of eIF2alpha. Hum Mol Genet 17(20):3254–3262. doi:10.1093/hmg/ddn221
Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J (2005) Rheb binds and regulates the mTOR kinase. Curr Biol CB 15(8):702–713. doi:10.1016/j.cub.2005.02.053
Ma M, Tian X, Igarashi P, Pazour GJ, Somlo S (2013) Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet 45(9):1004–1012. doi:10.1038/ng.2715
Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF (2007) Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132(3):1104–1116. doi:10.1053/j.gastro.2006.12.039
Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58(1):409–421. doi:10.1002/hep.26140
Mitchison JM (2003) Growth during the cell cycle. Int Rev Cytol 226:165–258
Portt L, Norman G, Clapp C, Greenwood M, Greenwood MT (2011) Anti-apoptosis and cell survival: a review. Biochim Biophys Acta 1813(1):238–259. doi:10.1016/j.bbamcr.2010.10.010
Riella C, Czarnecki PG, Steinman TI (2014) Therapeutic advances in the treatment of polycystic kidney disease. Nephron Clin Pract 128(3-4):297–302. doi:10.1159/000368244
Ruvinsky I, Meyuhas O (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31(6):342–348. doi:10.1016/j.tibs.2006.04.003
Santoso NG, Cebotaru L, Guggino WB (2011) Polycystin-1, 2, and STIM1 interact with IP(3)R to modulate ER Ca release through the PI3K/Akt pathway. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 27(6):715–726. doi:10.1159/000330080
Sorenson CM, Padanilam BJ, Hammerman MR (1996) Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Am J Phys 271(1 Pt 2):F184–F193
Tao Y, Kim J, Stanley M, He Z, Faubel S, Schrier RW, Edelstein CL (2005) Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD). Kidney Int 67(3):909–919. doi:10.1111/j.1523-1755.2005.00155.x
Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd (2004) Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10(4):363–364. doi:10.1038/nm1004
Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75(2):229–240
Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP (2006) Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc 21(3):598–604. doi:10.1093/ndt/gfi181
Wang X, Gattone V 2nd, Harris PC, Torres VE (2005) Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol JASN 16(4):846–851. doi:10.1681/ASN.2004121090
Wang X, Wu Y, Ward CJ, Harris PC, Torres VE (2008) Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol JASN 19(1):102–108. doi:10.1681/ASN.2007060688
Wang X, Ward CJ, Harris PC, Torres VE (2010) Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 77(2):129–140. doi:10.1038/ki.2009.438
Wolf BB, Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274(29):20049–20052
Woo D (1995) Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333(1):18–25. doi:10.1056/NEJM199507063330104
Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63(6):1983–1994. doi:10.1046/j.1523-1755.2003.00023.x
Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279(39):40419–40430. doi:10.1074/jbc.M405079200
Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12(1):9–18. doi:10.1038/sj.cr.7290105
Zhou XJ, Kukes G (1998) Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Diagn Mol Pathol Am J Sur Pathol B 7(2):65–68
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Lee, E.J. (2016). Cell Proliferation and Apoptosis in ADPKD. In: Park, J., Ahn, C. (eds) Cystogenesis. Advances in Experimental Medicine and Biology, vol 933. Springer, Singapore. https://doi.org/10.1007/978-981-10-2041-4_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-2041-4_3
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2040-7
Online ISBN: 978-981-10-2041-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)